Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference51 articles.
1. Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59(7):857–74.
2. Le Tilly O, Bejan-Angoulvant T, Paintaud G, et al. Letter to Dreesen et al. on their article “Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease”: a comprehensive review of infliximab population pharmacokinetic modelling publications. Br J Clin Pharmacol. 2020;2020:14554.
3. Berends SE, van Steeg TJ, Ahsman MJ, et al. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. J Pharmacokinet Pharmacodyn. 2019;46:543–51.
4. Furuya Y, Ozeki T, Takayanagi R, et al. Theory based analysis of anti-inflammatory effect of infliximab on Crohn’s disease. Drug Metab Pharmacokinet. 2007;22:20–5. https://doi.org/10.2133/dmpk.22.20.
5. Kimura K, Takayanagi R, Yokoyama H, et al. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn’s disease and rheumatoid arthritis. Rheumatol Int. 2012;32:145–50.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献